AbCellera Biologics Inc vs Twilio Inc — how do they compare? AbCellera Biologics Inc trades at $9.09 (market cap $2.85B), while Twilio Inc trades at $254.12 (market cap $38.40B). The key difference: Twilio Inc is far larger — about 13.5× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | TWLO | |
|---|---|---|
Market Cap | $2.85B | $38.40B |
Sector | Health | Technology |
52-Week High | $9.76 | $255.95 |
52-Week Low | $2.78 | $95.23 |
Enterprise Value | $2.45B | $36.81B |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Twilio (TWLO) trades at $241.28, up 24.89% in 24 hours, near its 52-week high. The stock is in a bullish technical trend with strong support at $228 and resistance at $255. Recent Q2 2026 earnings beat expectations with EPS of $1.47 versus $1.32 expected, and revenue grew 22% year-over-year to $1.5 billion. The company raised full-year 2026 revenue growth guidance to 18%-18.5%.
The outlook is positive with accelerating revenue growth and improving profitability, but risks include high valuation multiples and reliance on continued execution. Analyst consensus is strongly bullish with a $266.31 price target, though the stock's rapid ascent warrants caution near-term.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →